Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$273.29 USD

273.29
552,903

+1.58 (0.58%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $273.28 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 245)

Industry: Medical - Products

Zacks News

Sapna Bagaria headshot

New Coronavirus Strain to Keep Telehealth Stocks in Demand

Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.

Zacks Equity Research

QDEL vs. RMD: Which Stock Is the Better Value Option?

QDEL vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Urmimala Biswas headshot

5 Soaring MedTech Stocks to Buy for More Growth in 2021

We have selected five MedTech growth stocks with further rooms for improvement in 2021.

Swayta Shah headshot

5 Top Stocks With Attractive Sales Growth to Keep an Eye on

A steady sales growth is key to survival for any company. Let's check Broadcom (AVGO), PennyMac Financial (PFSI), ResMed (RMD) Williams-Sonoma (WSM) & Parker-Hannifin (PH) as these are likely to witness solid sales growth.

Zacks Equity Research

Here's Why You Should Hold onto NEOGEN (NEOG) Stock for Now

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

Debanjana Dey headshot

3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom

Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.

Zacks Equity Research

Bruker (BRKR) Launches PCR Panel, Expands Testing Portfolio

Bruker's (BRKR) winter four-plex panel is expected to facilitate diagnosis and patient management by facilitating the use of saliva samples as well.

Zacks Equity Research

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

    Zacks Equity Research

    Zacks.com featured highlights include: ResMed, The Toro Company, Masco Corp and Landstar System

    Zacks.com featured highlights include: ResMed, The Toro Company, Masco Corp and Landstar System

    Zacks Equity Research

    4 GARP Stocks to Scoop Up for Maximum Returns

    If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

    Debanjana Dey headshot

    5 MedTech Stocks That Have Outperformed the Industry in 2020

    Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.

    Zacks Equity Research

    Medtronic (MDT) Releases Positive Study Results of RFA Therapy

    Medtronic's (MDT) OsteoCool RFA System is expected to provide better relief from debilitating pain for cancer patients.

    Zacks Equity Research

    Here's Why You Should Add Hologic (HOLX) to Your Portfolio

    Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.

    Zacks Equity Research

    Zimmer Biomet (ZBH) Shows Strong Recovery Amid COVID-19 Woes

    Owing to lack of clarity around the scope and duration of the coronavirus pandemic, Zimmer Biomet (ZBH) is unable to gauge the impact on its overall business in 2020.

    Zacks Equity Research

    Abbott (ABT) Gains CE Mark for Quantitative Serology Testing

    The test is set to be used on Abbott's (ABT) ARCHITECT and Alinity i platforms.

    Zacks Equity Research

    Abbott (ABT) Launches Immunity Boosting Hydration Solution

    Abbott's (ABT) latest hydration solution with specifically chosen nutrients along with optimal balance of electrolytes and glucose is expected to boost immunity.

    Zacks Equity Research

    NEOGEN (NEOG) Launches DNA Screening Tool for Canine Care

    NEOGEN's (NEOG) latest DNA screening tool is expected to aid veterinarians to provide healthy lifestyle recommendations for a longer and happier life for each pet and its family.

    Zacks Equity Research

    LabCorp's (LH) Pixel Kit Gets EUA for Over-the-Counter Use

    This approval is expected to increase access to LabCorp's (LH) COVID-19 testing, thereby broadening its customer base.

    Zacks Equity Research

    Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market

    Medtronic's (MDT) Carpediem CRRT system compares favorably with the traditional three times a week therapy session.

      Zacks Equity Research

      Bruker (BRKR) Hits New 52-Week High: What's Driving It?

      Bruker (BRKR) is optimistic about maintaining a robust product portfolio along with its continued COVID-19-led progress.

      Zacks Equity Research

      Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access

      Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.

      Zacks Equity Research

      QIAGEN (QGEN) Launches RUO Solution to Explore Immune Response

      QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.

      Zacks Equity Research

      LabCorp (LH) Covance Arms Shows Momentum Amid COVID-19 Woes

      In oncology too, LabCorp (LH) receives a significant award to be the partner of choice for late-stage oncology studies from a major pharmaceutical company.

      Zacks Equity Research

      NuVasive (NUVA) Focuses on Cervical Spine Portfolio Expansion

      The ACP system within NuVasive (NUVA) C360 is targeted to reduce common postoperative complications such as dysphagia, malalignment and adjacent level ossification.